secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-08-04T11:02:24+00:00
Accession:  0001628280-26-052139
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q2 2026: first PROTAC approval (VEPPANU) and out-license to Rigel; cash $567.9M
--------------------------------------------------------------------------------

- First-ever FDA approval of a PROTAC degrader (VEPPANU) for ER+/HER2- ESR1-mutated breast cancer; out-licensed to Rigel Pharmaceuticals.
- Cash, cash equivalents, and marketable securities $567.9M as of June 30, 2026, down from $685.4M at Dec 31, 2025.
- GAAP R&D expenses $52.6M in Q2 2026 vs $68.6M in Q2 2025; decrease driven by lower compensation and vepdegestrant program costs.
- Pipeline milestones: data from ARV-393, ARV-102, ARV-027 expected over next 12 months; ARV-6723 Phase 1 initiation in 3Q 2026.
- Cash runway into second half of 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/0001628280-26-052139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/arvn-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-052139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer